Notice NOT-OD-26-004 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-161 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-161 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-449 from the NIH Guide for Grants and Contracts. The National Center for Complementary and Integrative Health (NCCIH) announces this Notice of Funding Opportunity (NOFO) to solicit applications for research on how mind and body interventions through psychological and/or physical inputs (e.g., mindfulness meditation, yoga, acupuncture, massage, and other brain and/or body based interventions) impact mechanisms of emotional well-being (EWB) and their associations with whole person health (WPH), consistent with the NIH priority to address the health needs of the American people and improve their well-being. The NOFO will support rigorous and well-powered mechanistic research studies that are supported by strong preliminary data. The studies should examine the effects of mind and body interventions on innovative mechanisms of EWB (as the primary outcome), as well as the associated relationship with the Whole Person Health Index (WPHI, as a secondary outcome). To enhance research safety, rigor, and efficiency of NIH-funded mechanistic clinical trials, this initiative will use a two-phased award funding mechanism (R61/R33). The funding will support an initial phase (R61) to establish feasibility benchmarks for the proposed mechanistic clinical trial(s), followed by a second phase (R33) to complete the full-scale trials, which will be contingent upon successful completion of R61 milestones. Applications should provide preliminary data that are comparable in quality and quantity to those expected for an R01 proposal.

Notice NOT-OD-25-163 from the NIH Guide for Grants and Contracts

Notice NOT-DE-26-012 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-160 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AI-25-012 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to solicit applications to participate in a consortium of Research Centers focused on designing, optimizing, evaluating, and developing broadly protective vaccines for hepatitis C virus to enable the advancement of vaccine candidates into clinical evaluation.

Funding Opportunity RFA-DA-26-020 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity seeks applications to establish and operate a dynamic and adaptable drug development infrastructure to support the research community. The aim is to strengthen and expand the substance use disorder (SUD) drug development pipeline by accelerating the evaluation and validation of repurposed and repositioned drugs. The Center and its team of subject matter experts will provide comprehensive drug development services to academic and biotech researchers at all stages of product development. By supporting various projects that address different SUD indications, the Center will contribute to reducing the burden of SUDs on individuals and communities. The services offered will include assistance in creating Target Product Profiles, Freedom-to-Operate analysis, intellectual property consultations, regulatory guidance, and technical pipeline support. Additionally, the Center will engage in outreach efforts to connect with the research community, solicit proposals, and implement processes to evaluate, select, and advance the projects focused on repurposing and repositioning medications for SUD treatment.

Notice NOT-OD-25-159 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-RM-25-006 from the NIH Guide for Grants and Contracts. The Common FundHuman Virome Program(HVP) aims to extensively and comprehensively characterize the human virome and create tools, models, and methods that will enable an in-depth study of its variation and composition in relation to host factors and its influence on health and disease. The purpose of this NOFO is to support small pilot projects that extend the goals of the HVP, including further validating, improving, and complementing existing and newly developed tools from the HVP program by leveraging human specimens collected from the cohorts under the program; samples from animals to promote the refinement, utilization, and translation of these tools to better serve the goals of the HVP program; expanding existing cohorts and/or biospecimen sampling sites for virome characterization; developing tools and methods to study the human virome; and defining interactions between the human virome and host. These pilot projects will encourage collaboration across the HVP and expand the consortium. Pilot projects should not overlap with existing HVP efforts. The R03 is intended to support small research projects that can be carried out in a short period of time with limited resources.

Funding Opportunity RFA-HD-26-001 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support and facilitate multidisciplinary research approaches for the development or improvement of technologies, including drugs, devices, products, or clinical practices designed to improve fertility outcomes in patients dealing with infertility, particularly in the context of Assisted Reproductive Technologies (ART). This NOFO aims to position innovative and validated technologies for future clinical development.

Notice NOT-LM-25-005 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-450 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The initiative seeks applications that are intended to facilitate rare diseases research by enabling efficient and effective movement of candidate therapeutics or diagnostics toward clinical trials, and to increase their likelihood of success. This could be through the development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.

Funding Opportunity PAR-25-447 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites applications to use NHLBI-funded TransOmics for Precision Medicine (TOPMed) program to generate a large volume of integrated genetic and multi-omics data to facilitate discovery of the molecular mechanisms of Heart, Lung, Blood, and Sleep (HLBS) disorders. No funding will be provided under this NOFO. The genomic data and related phenotypic data will be deposited in a public NIH-designated controlled-access database such as the database for Genotypes and Phenotypes (dbGaP) and NHLBIs BioData Catalyst (BDC). The overall goal is to move from simply cataloguing genetic associations to understanding how genetic factors contribute to HLBS diseases at the molecular and cellular levels. This transformation will help move TOPMed from genetic Map to Mechanism with potential applications of AI and ML tool sets where possible, enabling functional genomics research that will accelerate mechanistic personalized medicine

Funding Opportunity RFA-HL-26-006 from the NIH Guide for Grants and Contracts. The objective of this program is to create a consortium of clinical sites that will perform deep phenotyping in 1500 babies, infants, and toddlers (0-2 years of age) with viral lower respiratory tract infections (LRTI) and hospitalized with acute bronchiolitis, pneumonia and/or pediatric acute respiratory distress syndrome (PARDS), and longitudinal follow up of participants for evidence of lung disease including asthma at age 4-5 years. Bronchiolitis, a condition unique to the young lung, is the leading cause of hospitalization for viral LRTI in 02-year-old children, including those born preterm. There are critical knowledge gaps in defining the condition, predicting its severity, and understanding the reasons for hospitalization, including the immature host respiratory immune response to viral infection, heterogeneity in response to different viruses, current interventions, significant practice variation in diagnosis and management and subsequent impact on lung health. To meet the need for deep phenotyping, identify appropriate subgroups, refine the diagnosis and management of these vulnerable patients during their hospitalization, and identify prognostic biomarkers for future airway and parenchymal disease, we propose the VINYL (Viral INfections in the Young Lung) clinical consortium, a pragmatic observational study, to perform deep phenotypic characterization of 1500 babies, infants and toddlers admitted to the pediatric floor and pediatric intensive care unit with viral LRTI. A longitudinal follow-up of participants after discharge using electronic health records and questionnaires and assessment of respiratory status at age 4-5 years will elucidate pulmonary outcomes from early viral LRTI, specifically asthma. Neurocognitive and general development, and sleep will also be assessed during follow up.

Funding Opportunity RFA-AI-25-013 from the NIH Guide for Grants and Contracts. The goal of this notice of funding opportunity (NOFO) is to continue to provide operations support to the National Biocontainment Laboratories at the University of Texas Medical Branch (UTMB) in Galveston, Texas and Boston University in Boston, Massachusetts. Operations support is provided in the following areas: facility maintenance and operations; biosecurity; environmental health and safety regulations and requirements; regulatory compliance; and specialized research support services. The NBLs serve as a national resource for efforts in conducting pre-clinical and laboratory (in vitro and in vivo) research and testing on hazardous biological agents in support of NIAIDs biodefense and emerging infectious diseases research efforts. Additionally, in times of a national biodefense or emerging infectious disease (EID) emergency, the NBLs may be expected to rapidly realign their activities to assist response efforts within the US under the direction of NIAID.

Funding Opportunity RFA-HL-26-008 from the NIH Guide for Grants and Contracts. The objective of this program is to create a consortium of clinical sites that will perform deep phenotyping in 1500 babies, infants, and toddlers (0-2 years of age) with viral lower respiratory tract infections (LRTI) and hospitalized with acute bronchiolitis, pneumonia and/or the pediatric acute respiratory distress syndrome (PARDS), and longitudinal follow up of participants for evidence of lung disease including asthma at age 4-5 years. Bronchiolitis, a condition unique to the young lung, is the leading cause of hospitalization for viral LRTI in 02-year-old children, including those born preterm. There are critical knowledge gaps in defining the condition, predicting its severity, and understanding the reasons for hospitalization, including the immature host respiratory immune response to viral infection, heterogeneity in response to different viruses, current interventions, significant practice variation in diagnosis and management and subsequent impact on lung health.

Funding Opportunity PAR-25-439 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to support the development of innovative research centers to foster nursing-led programs that promote community-partnered research to address persistent health challenges. Center applications developed in response to this RFA should propose strategies to strengthen the research infrastructure by establishing or expanding centralized research resources in School or College of Nursing (SON/CON), developing and enhancing nurse-led interdisciplinary teams, and building expertise in community-partnered research through conducting pilot research that applies NINR's research lenses. Center strategies should be informed by NINRs mission and should meaningfully engage the community throughout all activities.

Funding Opportunity RFA-DK-26-315 from the NIH Guide for Grants and Contracts. This notice of funding opportunity (NOFO) invites applications designed to examine the efficacy and clinical effectiveness of multimodality digital health technology approaches to the remote management of diabetes.